| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Compared with H1975 cells with low GPC3 expression, 10P3Me (1 μCi per well; 0.5–4 h) showed significantly higher uptake in HepG2, Hep3B2.1–7 and Huh-7 cells with high GPC3 expression[1].
|
|---|---|
| ln Vivo |
10P3Me (200-300 μCi; intravenous injection) showed specific high tumor uptake and long retention time in subcutaneous HCC xenograft models with high GPC3 expression [1]. 10P3Me (150-200 μCi; intravenous injection) showed high peak tumor uptake and optimal tumor/liver ratio in HepG2 xenograft models [1].
|
| Animal Protocol |
Animal/Disease Models:Athymic nude mice (female, 4-6 weeks old, 18-22 g, subcutaneous xenograft hepatocellular carcinoma model)[1]
Doses: 200-300 μCi Route of Administration: Intravenous injection; static scans were performed at 60 and 120 minutes post-injection Experimental Results: In the HepG2 xenograft model, the peak tumor uptake reached 5.62% ID/mL 1 hour post-injection and 3.53% ID/mL 2 hours post-injection. The SUVmean reached 5.09% ID/mL 1 hour post-injection, which was 3.97 times higher than that of the H1975 model with low GPC3 expression. Tumor accumulation was significantly reduced in the blockade group and the H1975 model. Animal/Disease Models:Athymic nude mice (female, 4-6 weeks old, 18-22 g, orthotopic xenograft hepatocellular carcinoma model) [1] Doses: 200-300 μCi Route of Administration: Intravenous injection; PET imaging 1 hour after injection Experimental Results: PET/CT imaging clearly showed intrahepatic tumor lesions in the left lobe of the liver 1 hour after injection, and confirmed by surgical dissection. Animal/Disease Models:Athymic nude mice (female, 4-6 weeks old, 18-22 g, subcutaneous xenograft hepatocellular carcinoma model) [1] Doses: 150-200 μCi Route of Administration: Intravenous injection; assessed at 10, 30, 60, 120 and 240 minutes after injection Experimental Results: Tumor uptake reached its peak at 30 minutes after injection, at 6.92% ID/g. The tumor-to-liver uptake ratio reached 8.28 at 60 minutes after injection. |
| References |
| Molecular Formula |
C101H151N23O29S2
|
|---|---|
| Molecular Weight |
2215.55
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4514 mL | 2.2568 mL | 4.5136 mL | |
| 5 mM | 0.0903 mL | 0.4514 mL | 0.9027 mL | |
| 10 mM | 0.0451 mL | 0.2257 mL | 0.4514 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
